A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Stopped The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development. There were no safety/efficacy concerns behind the decision.
Conditions
Interventions
- DRUG: PF-03084014
- DRUG: PF-03084014
- DRUG: PF-03084014
- DRUG: Docetaxel
- DRUG: Docetaxel
Sponsor
Pfizer